Siyu Feng

Siyu Feng, PhD, currently serves as a Senior Scientist at BridgeBio Oncology Therapeutics, leading the cell biology team for the discovery and development of novel small molecule inhibitors within the “PI3Ka:RAS Breaker” program. Previously, Siyu held positions as a Senior Scientist and Scientist at BridgeBio, where significant contributions included conducting IND enabling studies and leading cell biology initiatives. Earlier experience includes a postdoctoral fellowship at Genentech, where Siyu utilized advanced techniques in gene engineering and bioinformatics to target oncogenic drivers. Siyu also participated as a finalist in the Merck Biopharma Innovation Cup and gained research experience as a graduate student researcher at the University of California, San Francisco, focusing on innovative protein technologies and cancer signaling mechanisms. Educational background comprises a dual PhD in Bioengineering and Biomedical Engineering from the University of California, San Francisco, and the University of California, Berkeley, complemented by a Bachelor's degree from Beihang University.